Poirier D, Bydal P, Tremblay M R, Sam K M, Luu-The V
Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center, Laval University Medical Centre (CHUL), 2705 Laurier Boulevard, G1V 4G2, Quebec, Canada.
Mol Cell Endocrinol. 2001 Jan 22;171(1-2):119-28. doi: 10.1016/s0303-7207(00)00427-5.
The 17beta-hydroxysteroid dehydrogenases (17beta-HSDs) are involved in the last step of the biosynthesis of sex steroids from cholesterol. This family of steroidogenic enzymes constitutes an interesting target in the control of the concentration of estrogens and androgens. Among the isoforms of 17beta-HSD, type II preferentially catalyzes the oxidation of estradiol (E(2)), testosterone (T), dihydrotestosterone (DHT), and 20alpha-dihydroprogesterone (20alpha-DHP). Based on structure-activity relationship studies, we have developed steroidal spirolactones as inhibitors of type II 17beta-HSD using different steroid nuclei: a C18-steroid (lactones 1 and 10), an antiestrogenic nucleus (lactone 2), and a C19-steroid (lactone 28). We know these inhibitors are selective for type II 17beta-HSD as no or only weak inhibition was observed for types I and III. They also have no proliferative (androgenic) activity on androgen sensitive (AR(+)) Shionogi cells whereas their proliferative (estrogenic) activity on estrogen sensitive (ER(+)) ZR-75-1 cells depends on the nature of the steroid nucleus. Lactones 1 and 10 are weak estrogens, while lactones 2 and 28 do not exert estrogenic activity, in fact lactone 2 is an antiestrogen. Lactones 1, 2, 10 and 28 were also tested in an identical assay with a series of enzyme substrates, C19-steroid diols, and known inhibitors, for the oxidation of testosterone and estradiol into androstenedione and estrone, respectively. From this comparative study, the best inhibitors of type II 17beta-HSD (oxidase activity) were identified, but none of them were clearly more potent than the hydroxylated (reduced) forms of enzyme substrates, E2, T, and DHT. Such inhibitors remain, however, useful tools to, (1) further elucidate the role of type II 17beta-HSD, and (2) regulate the level of active estrogens, androgens and progesterone.
17β-羟基类固醇脱氢酶(17β-HSDs)参与从胆固醇生物合成性类固醇的最后一步。这类类固醇生成酶是控制雌激素和雄激素浓度的一个有趣靶点。在17β-HSD的同工型中,II型优先催化雌二醇(E₂)、睾酮(T)、双氢睾酮(DHT)和20α-双氢孕酮(20α-DHP)的氧化。基于构效关系研究,我们利用不同的类固醇核开发了甾体螺内酯作为II型17β-HSD的抑制剂:一种C18-类固醇(内酯1和10)、一种抗雌激素核(内酯2)和一种C19-类固醇(内酯28)。我们知道这些抑制剂对II型17β-HSD具有选择性,因为对I型和III型未观察到抑制或仅观察到微弱抑制。它们对雄激素敏感(AR⁺)的史氏细胞也没有增殖(雄激素)活性,而它们对雌激素敏感(ER⁺)的ZR-75-1细胞的增殖(雌激素)活性取决于类固醇核的性质。内酯1和10是弱雌激素,而内酯2和28不具有雌激素活性,实际上内酯2是一种抗雌激素。内酯1、2、10和28也在相同的试验中与一系列酶底物、C19-类固醇二醇和已知抑制剂一起进行了测试,分别用于将睾酮和雌二醇氧化为雄烯二酮和雌酮。通过这项比较研究,确定了II型17β-HSD(氧化酶活性)的最佳抑制剂,但它们中没有一个明显比酶底物E₂、T和DHT的羟基化(还原)形式更有效。然而,这类抑制剂仍然是有用的工具,(1)用于进一步阐明II型17β-HSD的作用,以及(2)调节活性雌激素、雄激素和孕酮的水平。